4.42 USD
▲+0.17+28.12%
盘后 3.70 +7.17%
2026-08-03
市值
$5.16M
市盈率
—
EPS
-27.49
股息率
—
52 周区间
3.18 – 71.50
成交量
103.31K
Beta
2.51
目标价
—
52W 低 3.1852W 高 71.50
价格走势
公司简介
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutic...